111 related articles for article (PubMed ID: 9819832)
1. Understanding and testing for heterogeneity across 2 x 2 tables: application to meta-analysis.
Berry SM
Stat Med; 1998 Oct; 17(20):2353-69. PubMed ID: 9819832
[TBL] [Abstract][Full Text] [Related]
2. Cross-issue synthesis: potential application to breast cancer, tamoxifen and genetic susceptibility.
Nixon RM; Duffy SW
J Cancer Epidemiol Prev; 2002; 7(4):205-12. PubMed ID: 12846491
[TBL] [Abstract][Full Text] [Related]
3. Tamoxifen-treated breast carcinoma patients and the risk of acute myocardial infarction and newly diagnosed angina.
Geiger AM; Bernstein L
Cancer; 2006 Jan; 106(2):480-1; author reply 481. PubMed ID: 16311985
[No Abstract] [Full Text] [Related]
4. Sequential or concurrent tamoxifen and radiotherapy: to see or not to see--that is the question!
Bentzen SM; Yarnold JR
J Clin Oncol; 2005 Sep; 23(25):6266-7; author reply 6267. PubMed ID: 16135499
[No Abstract] [Full Text] [Related]
5. Bayesian meta-analysis: The role of the between-sample heterogeneity.
Moreno E; Vázquez-Polo FJ; Negrín MA
Stat Methods Med Res; 2018 Dec; 27(12):3643-3657. PubMed ID: 28511616
[TBL] [Abstract][Full Text] [Related]
6. HER2 status predicts for upfront AI benefit: A TRANS-AIOG meta-analysis of 12,129 patients from ATAC, BIG 1-98 and TEAM with centrally determined HER2.
Bartlett JMS; Ahmed I; Regan MM; Sestak I; Mallon EA; Dell'Orto P; Thürlimann B; Seynaeve C; Putter H; Van de Velde CJH; Brookes CL; Forbes JF; Viale G; Cuzick J; Dowsett M; Rea DW;
Eur J Cancer; 2017 Jul; 79():129-138. PubMed ID: 28494403
[TBL] [Abstract][Full Text] [Related]
7. Aromatase inhibitors for the treatment of breast cancer: is tamoxifen of historical interest only?
Van Poznak CH; Hayes DF
J Natl Cancer Inst; 2006 Sep; 98(18):1261-3. PubMed ID: 16985239
[No Abstract] [Full Text] [Related]
8. Meta-analysis for 2 x 2 tables: a Bayesian approach.
Carlin JB
Stat Med; 1992 Jan; 11(2):141-58. PubMed ID: 1349763
[TBL] [Abstract][Full Text] [Related]
9. LHRH-agonist versus chemotherapy in premenopausal breast cancer?
Klijn JG
Eur J Cancer; 2002 Nov; 38 Suppl 6():S45-6. PubMed ID: 12409071
[No Abstract] [Full Text] [Related]
10. Dissemination of adjuvant multiagent chemotherapy and tamoxifen for breast cancer in the United States using estrogen receptor information: 1975-1999.
Mariotto AB; Feuer EJ; Harlan LC; Abrams J
J Natl Cancer Inst Monogr; 2006; (36):7-15. PubMed ID: 17032888
[TBL] [Abstract][Full Text] [Related]
11. Don't think twice it's all right: tamoxifen and CYP2D6 genotyping in the treatment of breast cancer patients.
Damkier P
Pharmacogenomics; 2017 Jun; 18(8):753-754. PubMed ID: 28592184
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of tamoxifen as treatment of breast cancer.
Powles TJ
Semin Oncol; 1997 Feb; 24(1 Suppl 1):S1-48-S1-54. PubMed ID: 9045315
[TBL] [Abstract][Full Text] [Related]
13. Coronary heart disease mortality and adjuvant tamoxifen therapy.
Costantino JP; Kuller LH; Ives DG; Fisher B; Dignam J
J Natl Cancer Inst; 1997 Jun; 89(11):776-82. PubMed ID: 9182975
[TBL] [Abstract][Full Text] [Related]
14. A comparison of statistical methods for meta-analysis.
Brockwell SE; Gordon IR
Stat Med; 2001 Mar; 20(6):825-40. PubMed ID: 11252006
[TBL] [Abstract][Full Text] [Related]
15. A meta-analysis on the interaction between HER-2 expression and response to endocrine treatment in advanced breast cancer.
De Laurentiis M; Arpino G; Massarelli E; Ruggiero A; Carlomagno C; Ciardiello F; Tortora G; D'Agostino D; Caputo F; Cancello G; Montagna E; Malorni L; Zinno L; Lauria R; Bianco AR; De Placido S
Clin Cancer Res; 2005 Jul; 11(13):4741-8. PubMed ID: 16000569
[TBL] [Abstract][Full Text] [Related]
16. Tamoxifen for early breast cancer.
Early Breast Cancer Trialists' Collaborative Group
Cochrane Database Syst Rev; 2001; (1):CD000486. PubMed ID: 11279694
[TBL] [Abstract][Full Text] [Related]
17. Favorable cardiac risk among elderly breast carcinoma survivors.
Conti E; Marchese N; Andreotti F
Cancer; 2004 Feb; 100(4):878-9; author reply 879. PubMed ID: 14770447
[No Abstract] [Full Text] [Related]
18. Survival with aromatase inhibitors and inactivators versus standard hormonal therapy in advanced breast cancer: meta-analysis.
Mauri D; Pavlidis N; Polyzos NP; Ioannidis JP
J Natl Cancer Inst; 2006 Sep; 98(18):1285-91. PubMed ID: 16985247
[TBL] [Abstract][Full Text] [Related]
19. Multilevel models for meta-analysis, and their application to absolute risk differences.
Thompson SG; Turner RM; Warn DE
Stat Methods Med Res; 2001 Dec; 10(6):375-92. PubMed ID: 11763548
[TBL] [Abstract][Full Text] [Related]
20. Effects of hormones on the plasma levels of the atherogenic amino acid homocysteine.
Lien EA; Anker G; Lønning PE; Refsum H; Ueland PM
Biochem Soc Trans; 1997 Feb; 25(1):33-5. PubMed ID: 9056838
[No Abstract] [Full Text] [Related]
[Next] [New Search]
